drugset / Trial / NCT04428632

Oral Berotralstat Expanded Access Program

NCT04428632

Expanded access Approved for marketing BioCryst Pharmaceuticals

Summary

This expanded access program will provide access to berotralstat for eligible participants with hereditary angioedema in the U.S.

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background berotralstat Small molecule 150 mg Oral

Indications